<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04955834</url>
  </required_header>
  <id_info>
    <org_study_id>TQF2409-III-01</org_study_id>
    <nct_id>NCT04955834</nct_id>
  </id_info>
  <brief_title>A Clinical Study of Insulin Degludec Injection in Subjects With Type 2 Diabetes</brief_title>
  <official_title>A Multicenter, Randomized, Open-label, Parallel-controlled Phase III Clinical Study to Compare the Efficacy and Safety of Insulin Degludec Injection Versus Tresiba® in Subjects With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multi-center, randomized, open-label, parallel, positive-controlled&#xD;
      registered clinical study,to evaluate the efficacy and safety of insulin degludec injection&#xD;
      developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 27, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change value of glycosylated hemoglobin (HbA1c)</measure>
    <time_frame>Baseline and 26 weeks</time_frame>
    <description>Change value of HbA1c from baseline following 26 weeks of therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients achieving HbA1c ≤7% or HbA1c ≤6.5%</measure>
    <time_frame>Baseline, week 26</time_frame>
    <description>Percentage of patients in each arm achieving HbA1c ≤7% or HbA1c ≤6.5% after 26 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change value of HbA1c</measure>
    <time_frame>Baseline, week 14</time_frame>
    <description>Change value of HbA1c from baseline following 14 weeks of therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change value of fasting blood glucose</measure>
    <time_frame>Baseline, week 14, week 26</time_frame>
    <description>Change value of fasting blood glucose following 14 and 26 weeks of therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>Baseline to week 26</time_frame>
    <description>AEs and SAEs and their incidence during the 26-week treatment period, and then determine the correlation with the drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemia</measure>
    <time_frame>Baseline to week 26</time_frame>
    <description>Frequency of severe or symptomatic hypoglycemia during the 26-week treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>Baseline, week 14, week 26</time_frame>
    <description>The occurrence of immunogenicity during the 26-week treatment period by detecting Anti-Drug-Antibody(ADA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abnormal findings</measure>
    <time_frame>Baseline to week 26</time_frame>
    <description>Abnormal findings during the 26-week treatment period，including abnormal findings of blood routine test，blood biochemical test as well as other abnormal laboratory findings.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">344</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Insulin degludec injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Insulin degludec injection subcutaneous administration once daily for 26 weeks in combination with Oral antidiabetic drugs (OADs) used before.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tresiba®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Insulin degludec injection（Tresiba®）subcutaneous administration once daily for 26 weeks in combination with Oral antidiabetic drugs (OADs) used before.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin degludec injection</intervention_name>
    <description>long-acting insulin</description>
    <arm_group_label>Insulin degludec injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tresiba®</intervention_name>
    <description>long-acting insulin</description>
    <arm_group_label>Tresiba®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Type 2 diabetes (diagnosed clinically) for at least 6 months.&#xD;
&#xD;
          2. Aged ≥18 and ≤70 years old, male or female.&#xD;
&#xD;
          3. Subjects who were treated with a stable dose of oral hypoglycemic agents for more than&#xD;
             3 months before the random visit.&#xD;
&#xD;
          4. HbA1c is in the range of 7.5% -11.0 % by local laboratory analysis.&#xD;
&#xD;
          5. Body mass index (BMI) ≥18 kg/m2 and ≤40kg/m2.&#xD;
&#xD;
          6. Patients must give informed consent to this study before the trial, and voluntarily&#xD;
             sign an informed consent form.&#xD;
&#xD;
          7. Patients who can communicate well with the investigator and can complete the study in&#xD;
             accordance with the research regulations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Diagnosed as type 1 diabetes or other types of diabetes.&#xD;
&#xD;
          2. Patients who have received insulin therapy for more than 7 days within 3 months before&#xD;
             screening .&#xD;
&#xD;
          3. Patients who have received a thiazolidinedione (TZD) or GLP-1 receptor agonist within&#xD;
             3 months before screening.&#xD;
&#xD;
          4. Patients who are receiving or have received chronic (lasting more than 2 weeks)&#xD;
             systemic glucocorticoid therapy (excluding topical drugs and inhaled preparations)&#xD;
             within 3 months before the random visit.&#xD;
&#xD;
          5. Patients who are receiving or have received chronic (lasting more than 2 weeks)&#xD;
             systemic glucocorticoid therapy (excluding topical drugs and inhaled preparations)&#xD;
             within 3 months before the random visit.&#xD;
&#xD;
          6. Patients with hypoglycemia who have recurring severe events with conscious and/or&#xD;
             physical changes within 3 months before screening and need help from others.&#xD;
&#xD;
          7. Those who have experienced acute metabolic complications (ketoacidosis, lactic&#xD;
             acidosis, or hyperosmolar coma, etc.) within 3 months before screening.&#xD;
&#xD;
          8. Patients with obvious liver and kidney dysfunction.&#xD;
&#xD;
          9. Hemoglobin &lt;100g/L.&#xD;
&#xD;
         10. When the virological test during the screening period shows that any of the following&#xD;
             is met:&#xD;
&#xD;
        (1) HCV（hepatitis C virus） antibody is positive, and the HCV virus titer test value exceeds&#xD;
        the upper limit of normal value; (2) HBsAg（Hepatitis B surface antigen） is positive and the&#xD;
        HBV（hepatitis B virus） DNA test value exceeds the upper limit of normal; (3) HIV（human&#xD;
        immunodeficiency virus） positive; (4) Active syphilis;&#xD;
&#xD;
        11. At the time of screening, there are thyroid diseases that have not been controlled with&#xD;
        stable doses of drugs within 6 months, and the results of thyroid function tests during the&#xD;
        screening period are abnormal and have clinical significance.&#xD;
&#xD;
        12. Uncontrolled or poorly treated high blood pressure.&#xD;
&#xD;
        13. Those with decompensated heart failure (NYHA class III and IV), unstable angina, stroke&#xD;
        or transient ischemic attack, myocardial infarction, severe arrhythmia, cardiac surgery or&#xD;
        blood vessel reconstruction (including coronary artery bypass grafting or percutaneous&#xD;
        coronary intervention) occurred within 6 months before screening.&#xD;
&#xD;
        14. Those with proliferative retinopathy or macular degeneration (macular edema) that&#xD;
        requires urgent treatment during screening.&#xD;
&#xD;
        15. Once diagnosed as malignant tumor (except for basal cell carcinoma or squamous cell&#xD;
        skin cancer).&#xD;
&#xD;
        16. Patients with severe chronic gastrointestinal diseases (such as active peptic ulcer)&#xD;
        and severe infections.&#xD;
&#xD;
        17. Those who are allergic to any ingredient in insulin deglu injection and Novota®.&#xD;
&#xD;
        18.Those who participated in any other clinical trials within 3 months before screening&#xD;
        (excluding those who failed the screening or did not use study drugs for other reasons).&#xD;
&#xD;
        19. Pregnant women, lactating women, women of childbearing age who do not take appropriate&#xD;
        contraceptive measures during the trial period (sterilization, intrauterine device, oral&#xD;
        contraceptives or barrier contraception).&#xD;
&#xD;
        20. Those who are judged by the investigator to be unsuitable to participate in the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhiguang Zhou, Doctor</last_name>
    <phone>0731-85294018</phone>
    <email>zhouzg@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Qifu Li, Doctor</last_name>
    <phone>023-89012755</phone>
    <email>liqifu@yeah.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qifu Li, Doctor</last_name>
      <phone>023-89012755</phone>
      <email>liqifu@yeah.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhiguang Zhou, Doctor</last_name>
      <phone>0731-85294018</phone>
      <email>zhouzg@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 5, 2021</study_first_submitted>
  <study_first_submitted_qc>July 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2021</study_first_posted>
  <last_update_submitted>September 18, 2021</last_update_submitted>
  <last_update_submitted_qc>September 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

